CY1111516T1 - Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους - Google Patents

Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Info

Publication number
CY1111516T1
CY1111516T1 CY20111100530T CY111100530T CY1111516T1 CY 1111516 T1 CY1111516 T1 CY 1111516T1 CY 20111100530 T CY20111100530 T CY 20111100530T CY 111100530 T CY111100530 T CY 111100530T CY 1111516 T1 CY1111516 T1 CY 1111516T1
Authority
CY
Cyprus
Prior art keywords
methods
analoges
macrocycle
preparation
mitotic
Prior art date
Application number
CY20111100530T
Other languages
Greek (el)
English (en)
Inventor
Bruce A Littlefield
Monica Palme
Boris M Seletsky
Murray J Towle
Melvin J Yu
Wanjun Zheng
Original Assignee
Eisai R&D Management Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd filed Critical Eisai R&D Management Co., Ltd
Publication of CY1111516T1 publication Critical patent/CY1111516T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CY20111100530T 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους CY1111516T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
EP99928746A EP1087960B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (1)

Publication Number Publication Date
CY1111516T1 true CY1111516T1 (el) 2014-04-09

Family

ID=22219026

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100530T CY1111516T1 (el) 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
CY2011010C CY2011010I1 (el) 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2011010C CY2011010I1 (el) 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Country Status (22)

Country Link
US (4) US6214865B1 (enExample)
EP (4) EP2272839B1 (enExample)
JP (1) JP4454151B2 (enExample)
KR (1) KR100798600B1 (enExample)
CN (1) CN1216051C (enExample)
AT (1) ATE502932T1 (enExample)
AU (1) AU762998B2 (enExample)
BE (1) BE2011C028I2 (enExample)
BR (1) BRPI9911326B8 (enExample)
CA (3) CA2632433C (enExample)
CY (2) CY1111516T1 (enExample)
DE (2) DE122011100031I1 (enExample)
DK (1) DK1087960T3 (enExample)
FR (1) FR11C0038I2 (enExample)
HU (1) HU227912B1 (enExample)
IL (1) IL139960A0 (enExample)
LU (1) LU91854I2 (enExample)
NO (5) NO328280B1 (enExample)
NZ (1) NZ508597A (enExample)
PT (1) PT1087960E (enExample)
WO (1) WO1999065894A1 (enExample)
ZA (1) ZA200007159B (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632433C (en) * 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2003082268A2 (en) 2002-03-22 2003-10-09 Eisai Co. Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
CA2526385C (en) * 2003-05-29 2008-07-22 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005011589A2 (en) * 2003-07-29 2005-02-10 Eisai Co., Ltd. Drug delivery methods and devices
KR101434673B1 (ko) * 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
CN108997267A (zh) * 2004-06-03 2018-12-14 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
EP2578576B9 (en) * 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
RU2517167C2 (ru) * 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
PE20120923A1 (es) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
WO2010119890A1 (ja) * 2009-04-14 2010-10-21 日産化学工業株式会社 テトラヒドロピラン化合物の製造方法およびその中間体
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
IN2014MN01521A (enExample) * 2011-12-29 2015-05-01 Alphora Res Inc
CN104334562A (zh) * 2012-03-30 2015-02-04 阿方拉研究股份有限公司 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
CN105338977B (zh) 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
CA2929084C (en) 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b
BR112016012237B1 (pt) 2013-12-06 2023-02-07 Eisai R&D Management Co., Ltd Métodos úteis na síntese de análogos de halicondrina b
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
WO2015183961A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MX386547B (es) * 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) * 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
MX377663B (es) 2016-02-12 2025-03-11 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN109415383A (zh) * 2016-05-26 2019-03-01 雷迪博士实验室有限公司 制备艾日布林的方法及其中间体
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201902974PA (en) 2016-10-14 2019-05-30 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
BR112019010494A2 (pt) * 2016-11-23 2019-09-17 Dr Reddys Laboratories Ltd processo para a preparação de eribulina e intermediários do mesmo
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN110139866B (zh) * 2017-01-02 2022-05-17 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体以及制备其的方法
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SI3606928T1 (sl) 2017-04-05 2023-02-28 President And Fellows Of Harvard College Makrociklična spojina in njene uporabe
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019093776A1 (ko) 2017-11-09 2019-05-16 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN111566113B (zh) 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
MX2020006945A (es) 2018-01-03 2020-11-09 Eisai R&D Man Co Ltd Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN112437775A (zh) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 用于制备艾日布林及其中间体的纯化方法
WO2020075027A1 (en) * 2018-10-09 2020-04-16 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020110146A1 (en) * 2018-11-28 2020-06-04 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
CN113766914B (zh) 2018-12-20 2024-02-13 美商奥润沙公司 戊烷脒的类似物和其用途
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US12247239B2 (en) 2019-06-21 2025-03-11 Council Of Scientific & Industrial Research Chemo-enzymatic process for the preparation of homopropargylic alcohol
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
AU2024209545A1 (en) * 2023-01-17 2025-08-07 Systimmune, Inc. Conjugate of eribulin drug
EP4725969A1 (en) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
CN118834221B (zh) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 一种软海绵素b类似物
CN122349614A (zh) 2023-10-13 2026-07-07 卫材R&D管理有限公司 抗体-药物缀合物代谢物
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (zh) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 艾日布林衍生物及其抗体药物偶联物和医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
CA2632433C (en) * 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
EP2578576B9 (en) * 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
CN101910180A (zh) * 2007-11-16 2010-12-08 卫材R&D管理有限公司 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
RU2517167C2 (ru) * 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
US8203010B2 (en) * 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs

Also Published As

Publication number Publication date
KR20010083050A (ko) 2001-08-31
WO1999065894A1 (en) 1999-12-23
US8148554B2 (en) 2012-04-03
US6365759B1 (en) 2002-04-02
EP2272839A1 (en) 2011-01-12
DK1087960T3 (da) 2011-06-14
NO20093217L (no) 2001-02-15
CA2335300C (en) 2008-10-07
HU227912B1 (en) 2012-05-29
CA2755266A1 (en) 1999-12-23
ZA200007159B (en) 2001-12-04
NO20006316D0 (no) 2000-12-12
NO2022019I1 (no) 2022-06-03
CA2632433A1 (en) 1999-12-23
NZ508597A (en) 2004-01-30
BE2011C028I2 (en) 2018-08-24
ATE502932T1 (de) 2011-04-15
US6469182B1 (en) 2002-10-22
JP2002518384A (ja) 2002-06-25
NO2011026I2 (no) 2012-06-11
NO331183B1 (no) 2011-10-24
EP2272840A1 (en) 2011-01-12
HUP0103357A3 (en) 2002-10-28
LU91854I2 (fr) 2011-10-17
RU2245335C2 (ru) 2005-01-27
NO2011026I1 (no) 2012-01-09
PT1087960E (pt) 2011-06-17
FR11C0038I2 (fr) 2013-01-11
AU4573999A (en) 2000-01-05
CN1216051C (zh) 2005-08-24
HK1035534A1 (en) 2001-11-30
EP2277873B1 (en) 2012-05-30
BR9911326A (pt) 2001-04-03
US6214865B1 (en) 2001-04-10
KR100798600B1 (ko) 2008-01-28
AU762998C (en) 2000-01-05
EP2277873A1 (en) 2011-01-26
IL139960A0 (en) 2002-02-10
CA2335300A1 (en) 1999-12-23
NO328280B1 (no) 2010-01-25
DE69943296D1 (de) 2011-05-05
HUP0103357A2 (hu) 2002-01-28
BRPI9911326B8 (pt) 2021-05-25
CN1312804A (zh) 2001-09-12
BR9911326B1 (pt) 2015-01-06
EP2272839B1 (en) 2012-08-22
NO2011018I1 (no) 2011-09-26
DE122011100031I1 (de) 2011-12-15
EP2272840B1 (en) 2012-08-22
NO20006316L (no) 2001-02-15
CA2632433C (en) 2012-02-07
EP1087960A4 (en) 2004-12-01
EP1087960A1 (en) 2001-04-04
CY2011010I2 (el) 2014-04-09
EP1087960B1 (en) 2011-03-23
US20110172446A1 (en) 2011-07-14
AU762998B2 (en) 2003-07-10
CA2755266C (en) 2014-08-12
JP4454151B2 (ja) 2010-04-21
CY2011010I1 (el) 2014-04-09
FR11C0038I1 (fr) 2011-10-14

Similar Documents

Publication Publication Date Title
BRPI9911326B8 (pt) análogos macrocíclicos e métodos para seu uso e preparação
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
TR200100054T2 (tr) Paroksetin metansülfonat
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
BR0314354A (pt) Formação para gentes lipofìlicos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CY1110426T1 (el) Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων
CY1106600T1 (el) Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης
TR200003801T2 (tr) Acı hafifletmek için deri üstü kompozisyonlar ve yöntemler
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
CY1114062T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
EP1478406A4 (en) COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
DE60128216D1 (de) Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
DE69905170T2 (de) Thiazolopyrimidinderivate
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
DK1036059T3 (da) Adamantanderivater
PT839143E (pt) Compostos de tetralina com actividade mdr
TR200100172T2 (tr) Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos